Syncona — 2020 Investments

3 investments dated 2020 · listed companies and verified rows first · show all

Neogene Therapeuticsneogene.comSep 2020 · $110MAcquired

Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.

BiotechNew York, US

Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)

BoardDavid M. Tanen(Director, Promoter)Helen Kim(Director)

Board seatElisa Petris· per SEC Form D

Co-investorsEcoR1 Capital Jeito Capital Vida Ventures TPG

Salvia Bioelectronicssalviabioelectronics.comSeries A · Sep 2020 · $31M

Neuromodulation therapy for migraine relief.

Eindhoven, NL

Hubert Martens(Co-founder; Chief Executive Officer)Daniel Schobben(Co-founder; Chief Innovation Officer)Dr. Wim Pollet(Co-founder; Chief Medical Officer)

Co-investorsDolby Family Ventures Inkef Innovation Industries Levensohn Venture Partners Panakes Partners SHS Capital +1 more

VarmXvarmx.com inSeries B · Jul 2020 · $36M

VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings.

BiotechHealthtechMedical Devices

Pieter Reitsma(Founder)inJohn Glasspool(Chief Executive Officer)in

Co-investorsBioGeneration Ventures Inkef Sound Bioventures Ysios Capital EIC EQT Life Sciences +3 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.